These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23880202)

  • 1. HPS2-THRIVE results: bad for niacin/laropiprant, good for ezetimibe?
    Masana L; Cabré A; Plana N
    Atherosclerosis; 2013 Aug; 229(2):449-50. PubMed ID: 23880202
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
    Westerink J; Visseren FL
    Eur J Clin Invest; 2010 Jan; 40(1):87. PubMed ID: 19912317
    [No Abstract]   [Full Text] [Related]  

  • 3. Trial clouds use of niacin with a statin.
    Harv Heart Lett; 2011 Aug; 21(12):2. PubMed ID: 21991606
    [No Abstract]   [Full Text] [Related]  

  • 4. HDL and LDL as therapeutic targets for cardiovascular disease prevention: the possible role of niacin.
    Olsson AG
    Nutr Metab Cardiovasc Dis; 2010 Oct; 20(8):553-7. PubMed ID: 20739153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs.
    Kent S; Haynes R; Hopewell JC; Parish S; Gray A; Landray MJ; Collins R; Armitage J; Mihaylova B;
    Circ Cardiovasc Qual Outcomes; 2016 Jul; 9(4):348-54. PubMed ID: 27407053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular primary prevention: how high should we set the bar?
    Prasad V; Vandross A
    Arch Intern Med; 2012 Apr; 172(8):656-9; discussion 659. PubMed ID: 22529231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simvastatin with or without ezetimibe in familial hypercholesterolemia.
    Kaye T
    N Engl J Med; 2008 Jul; 359(5):531-2; author reply 532-3. PubMed ID: 18677800
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany.
    Michailov GV; Davies GM; Krobot KJ
    Eur J Health Econ; 2012 Jun; 13(3):365-74. PubMed ID: 21465286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ARBITER 6-HALTS. Does it have the power to settle all matters?
    Ferrario CM
    Ther Adv Cardiovasc Dis; 2010 Apr; 4(2):77-81. PubMed ID: 20360390
    [No Abstract]   [Full Text] [Related]  

  • 11. Lipid disorders.
    Kole LA
    JAAPA; 2009 Nov; 22(11):54-5. PubMed ID: 19999177
    [No Abstract]   [Full Text] [Related]  

  • 12. In brief: Ezetimibe/simvastatin (Vytorin) in chronic kidney disease.
    Med Lett Drugs Ther; 2012 Jan; 54(1381):4. PubMed ID: 22233589
    [No Abstract]   [Full Text] [Related]  

  • 13. Is there a problem with ezetimibe or just ENHANCEd hype?
    Whayne TF
    Angiology; 2008 Dec-2009 Jan; 59(6):661-3. PubMed ID: 18796445
    [No Abstract]   [Full Text] [Related]  

  • 14. [Innovative therapies in metabolic diseases: ezetimibe (Ezétrol), nicotinic acid (Niaspan), acids omega-3 (Omacor), rimonabant (Acomplia)].
    Ducobu J
    Rev Med Brux; 2005 Sep; 26(4):S393-405. PubMed ID: 16240893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niacin compared with ezetimibe.
    Duivenvoorden R; Vergeer M; Kastelein JJ
    N Engl J Med; 2010 Mar; 362(11):1046-7; author reply 1048. PubMed ID: 20301795
    [No Abstract]   [Full Text] [Related]  

  • 16. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
    Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J
    Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.
    Haynes R; Valdes-Marquez E; Hopewell JC; Chen F; Li J; Parish S; Landray MJ; Armitage J; ; ;
    Clin Ther; 2019 Sep; 41(9):1767-1777. PubMed ID: 31447131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-lowering effects of ezetimibe and simvastatin in combination.
    Ijioma N; Robinson JG
    Expert Rev Cardiovasc Ther; 2011 Feb; 9(2):131-45. PubMed ID: 21453210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
    Blazing MA; Giugliano RP; Cannon CP; Musliner TA; Tershakovec AM; White JA; Reist C; McCagg A; Braunwald E; Califf RM
    Am Heart J; 2014 Aug; 168(2):205-12.e1. PubMed ID: 25066560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ezetimibe and recent clinical trials: a look on the bright side.
    Ahmed MH
    Expert Opin Drug Saf; 2010 Jul; 9(4):511-4. PubMed ID: 20377476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.